QURE · uniQure N.V.
$44.51
+0.09% last session
End-of-day data · close of 2026-09-11
Market cap
$3B
Enterprise value
$3B
Trailing P/E
—
Forward P/E
-16.9
Dividend yield
—
Beta
0.94
Avg volume
2M
Employees
0K
Daily Change %
0.09%
5 Days Change
3.37%
10 Days Change
-5.51%
30 Days Change
2.22%
60 Days Change
7.91%
Month to Day Change
-3.89%
Year to Day Change
92.23%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — QURE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-30
Latest call per bank · past 12 months
Wells Fargo
Overweight$75.00
+68.7% vs priceBarclays
Overweight$60.00
+34.9% vs priceGoldman Sachs
Neutral$46.00
+3.4% vs priceRBC Capital
Outperform$65.00
+46.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-30 | Wells Fargo | Maintains | Overweight | $60.00 → $75.00 |
| 2026-07-30 | Wolfe Research | Upgrade | Peer Perform → Outperform | $0.00 → $65.00 |
| 2026-07-30 | Barclays | Maintains | Overweight | $65.00 → $60.00 |
| 2026-06-29 | HC Wainwright & Co. | Maintains | Buy | $50.00 → $80.00 |
| 2026-06-25 | Mizuho | Maintains | Outperform | $35.00 → $68.00 |
| 2026-06-18 | Barclays | Upgrade | Equal-Weight → Overweight | $25.00 → $65.00 |
| 2026-06-18 | Goldman Sachs | Maintains | Neutral | $14.00 → $46.00 |
| 2026-06-18 | Leerink Partners | Maintains | Outperform | $36.00 → $70.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 44 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.5% above the 50-day MA ($44.31).
- Price vs 200-day MA: Trading 55.1% above the 200-day MA ($28.69).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.72) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($9.03) and high ($70.59).
QURE Price Chart
Loading chart for QURE…
Fundamentals
About uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.